- Home
- PALI vs ANGO Comparison
PALI vs ANGO Comparison
Compare PALI & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | ANGO |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.7M | 420.2M |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | PALI | ANGO |
|---|---|---|
| Price | $1.95 | $12.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $11.29 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.5M | 327.6K |
| Earning Date | 05-11-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | 81.92 |
| EPS | ★ N/A | N/A |
| Revenue | $260,000.00 | ★ $291,010,000.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | 10.17 |
| 52 Week Low | $0.55 | $8.36 |
| 52 Week High | $2.86 | $13.99 |
Technical Indicators
Market Signals| Indicator | PALI | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 68.09 |
| Support Level | $1.57 | $13.02 |
| Resistance Level | $2.12 | $13.37 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 75.00 | 100.00 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.